JNJ Presents New Data on Psychiatric Medications at Psych Congress

Johnson & Johnson (JNJ) is presenting new data on its psychiatric medications at the Psych Congress 2026 meeting. The company will share Phase 3 results for CAPLYTA in bipolar mania, as well as new findings for mood disorder therapies SPRAVATO and seltorexant across multiple neuropsychiatric indications.

The clinical updates highlight progress in Johnson & Johnson's pharmaceutical pipeline and may influence future regulatory decisions in mental health treatments. The data is significant because it puts Johnson & Johnson's mood disorder franchise in front of a specialist audience at scale, which can shape how clinicians view the portfolio.

The news is not surprising, as Johnson & Johnson has been relying on new therapies such as CAPLYTA and SPRAVATO to support analyst expectations for 7.2% annual revenue growth and higher margins through 2029. However, longer-running risks like STELARA loss of exclusivity and talc litigation still sit in the background.

The key test now is what happens after the meeting, including any regulatory filings or label expansion moves tied to the CAPLYTA Phase 3 data, as well as how quickly usage trends for SPRAVATO and future seltorexant indications show up in reported segment sales. Conference feedback, guideline references, and management commentary on upcoming earnings calls will be the clearest early markers.